EvaluatePharma has estimated sales of this drug at $ 1.3 billion in 2024, making it an important part of the late-stage Novartis pipeline and a hallmark for development director John Tsai and the director. General, Vas Narasimhan, who entrusted him with the post when he was promoted to the world.

To read this article, you must be a subscriber to Endpoints News. (The subscription is free.)

The best place to read News on the end points? In your inbox.

Complete daily report for those who discover, develop and market drugs. Join 45 200+ biopharmacy professionals who read News on the end points by email every day.

Free subscription